These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 16392142)

  • 21. Experimental evaluation of possible side effects of intra-operative photodynamic therapy on rabbit blood vessels and nerves.
    Kübler AC; Stenzel W; Rühling M; Meul B; Fischer JH
    Lasers Surg Med; 2003; 33(4):247-55. PubMed ID: 14571449
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential of magnetic resonance spectroscopic imaging in predicting absence of prostate cancer in men with serum prostate-specific antigen between 4 and 10 ng/ml: a follow-up study.
    Kumar R; Nayyar R; Kumar V; Gupta NP; Hemal AK; Jagannathan NR; Dattagupta S; Thulkar S
    Urology; 2008 Oct; 72(4):859-63. PubMed ID: 18329078
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Photodynamic therapy as novel nephron sparing treatment option for small renal masses.
    Kroeze SG; Grimbergen MC; Rehmann H; Bosch JL; Jans JJ
    J Urol; 2012 Jan; 187(1):289-95. PubMed ID: 22099991
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lipophilic photosensitizer administration via the prostate arteries for photodynamic therapy of the canine prostate.
    Xiao Z; Owen RJ; Liu W; Tulip J; Brown K; Woo T; Moore RB
    Photodiagnosis Photodyn Ther; 2010 Jun; 7(2):106-14. PubMed ID: 20510305
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Photodynamic therapy (PDT) for oesophageal dysplasia and early carcinoma with mTHPC (m-Tetrahidroxyphenyl chlorin): a preliminary study.
    Javaid B
    Lasers Med Sci; 2002; 17(2):135. PubMed ID: 12143833
    [No Abstract]   [Full Text] [Related]  

  • 26. Outcome of mTHPC mediated photodynamic therapy is primarily determined by the vascular response.
    Triesscheijn M; Ruevekamp M; Aalders M; Baas P; Stewart FA
    Photochem Photobiol; 2005; 81(5):1161-7. PubMed ID: 15934792
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels.
    Lawrentschuk N; Fleshner N
    BJU Int; 2009 Mar; 103(6):730-3. PubMed ID: 19154475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment planning and dose analysis for interstitial photodynamic therapy of prostate cancer.
    Davidson SR; Weersink RA; Haider MA; Gertner MR; Bogaards A; Giewercer D; Scherz A; Sherar MD; Elhilali M; Chin JL; Trachtenberg J; Wilson BC
    Phys Med Biol; 2009 Apr; 54(8):2293-313. PubMed ID: 19305043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Validity of prostate-specific antigen as a tumour marker in men with prostate cancer managed by watchful-waiting: correlation with findings at serial endorectal magnetic resonance imaging and spectroscopic imaging.
    Coakley FV; Chen I; Qayyum A; Westphalen AC; Carroll PR; Hricak H; Chen MH; Kurhanewicz J
    BJU Int; 2007 Jan; 99(1):41-5. PubMed ID: 17227490
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsies.
    Anastasiadis AG; Lichy MP; Nagele U; Kuczyk MA; Merseburger AS; Hennenlotter J; Corvin S; Sievert KD; Claussen CD; Stenzl A; Schlemmer HP
    Eur Urol; 2006 Oct; 50(4):738-48; discussion 748-9. PubMed ID: 16630688
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The pharmacokinetic behavior of the photosensitizer meso-tetra-hydroxyphenyl-chlorin in mice and men.
    Triesscheijn M; Ruevekamp M; Out R; Van Berkel TJ; Schellens J; Baas P; Stewart FA
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):113-22. PubMed ID: 17009028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimizing light dosimetry in photodynamic therapy of early stage carcinomas of the esophagus using fluorescence spectroscopy.
    Braichotte DR; Savary JF; Monnier P; van den Bergh HE
    Lasers Surg Med; 1996; 19(3):340-6. PubMed ID: 8923430
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy.
    Pruthi RS; Derksen JE; Moore D; Carson CC; Grigson G; Watkins C; Wallen E
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2172-7. PubMed ID: 16609031
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostate volume measured preoperatively predicts for organ-confined disease in men with clinically localized prostate cancer.
    Bianco FJ; Mallah KN; Korets R; Hricak H; Scardino PT; Kattan MW
    Urology; 2007 Feb; 69(2):343-6. PubMed ID: 17320675
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cellular and molecular effects of the liposomal mTHPC derivative Foslipos in prostate carcinoma cells in vitro.
    Gyenge EB; Hiestand S; Graefe S; Walt H; Maake C
    Photodiagnosis Photodyn Ther; 2011 Jun; 8(2):86-96. PubMed ID: 21497299
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intralesional recombinant alpha-interferon for localized prostate cancer: a pilot study with follow-up of >10 years.
    Emerson L; Morales A
    BJU Int; 2009 Oct; 104(8):1068-70. PubMed ID: 19338545
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Photophysical parameters, photosensitizer retention and tissue optical properties completely account for the higher photodynamic efficacy of meso-tetra-hydroxyphenyl-chlorin vs Photofrin.
    Mitra S; Foster TH
    Photochem Photobiol; 2005; 81(4):849-59. PubMed ID: 15807635
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Photodynamic therapy for cancer of the upper aerodigestive tract using tetra(m-hydroxyphenyl)chlorin.
    Grosjean P; Savary JF; Mizeret J; Wagnieres G; Woodtli A; Theumann JF; Fontolliet C; Van den Bergh H; Monnier P
    J Clin Laser Med Surg; 1996 Oct; 14(5):281-7. PubMed ID: 9612194
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Individualized prostate biopsy strategy for Chinese patients with different prostate-specific antigen levels.
    Dai B; Ye DW; Kong YY; Shen YJ; Wang BH
    Asian J Androl; 2008 Mar; 10(2):325-31. PubMed ID: 18097514
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Photodynamic therapy for prostate cancer--an emerging approach for organ-confined disease.
    Moore CM; Emberton M; Bown SG
    Lasers Surg Med; 2011 Sep; 43(7):768-75. PubMed ID: 22057504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.